Background
==========

Riociguat is the first oral, soluble guanylate cyclase stimulator under review for the treatment of pulmonary hypertension (PH), a progressive, ultimately fatal disease \[[@B1]-[@B7]\]. This pooled analysis of two studies evaluated the pharmacokinetics of riociguat and its metabolite M1 (BAY 60-4552) in individuals with and without renal impairment. The safety and tolerability of riociguat were also assessed.

Methods
=======

Two non-randomized, non-blinded, observational studies with group stratification were conducted in a single centre in Germany, following Good Clinical Practice and relevant industry guidelines \[[@B8],[@B9]\]. Participants were assigned to one of four renal function groups according to their creatinine clearance (CL~CR~): group 1, CL~CR~ \> 80 mL/min; group 2, CL~CR~ 50--80 mL/min; group 3, CL~CR~ 30--49 mL/min; group 4, CL~CR~ \< 30 mL/min. In the first study, individuals in group 4 received riociguat 0.5 mg; all other participants in both studies received riociguat 1 mg (single tablet doses). Pharmacokinetic parameters were assessed using dense sampling.

Results
=======

Sixty-three participants (40 men and 23 women; mean age, 61.3 years \[range, 36--78 years\]) completed the study and were eligible for pharmacokinetic analysis. Riociguat was rapidly absorbed; median time to reach maximum concentration in plasma (t~max~) (C~max~) was 1 hour in all four groups. Mean half-life of total riociguat was longer in groups 2--4 (9.5--11.4 hours) than in group 1 (6.2 hours) (Table [1](#T1){ref-type="table"}), and renal clearance of riociguat decreased with decreasing renal function. Mean exposure to total riociguat (area under the concentration--time curve divided by dose per kilogram of body weight \[AUC~norm~\]) was 42.7--104.3% higher in groups 2--4 than in group 1 (Table [1](#T1){ref-type="table"}, Figure [1](#F1){ref-type="fig"}). However, exposure was highly variable in groups 2--4 and the exposure ranges in all groups overlapped (Figure [1](#F1){ref-type="fig"}). Exposure to riociguat did not increase strictly in parallel with decreasing CL~CR~. Results for unbound riociguat and M1 were similar to those for total riociguat and M1. No serious or severe adverse events were reported. Headache was the most common drug-related adverse event. No changes in safety or tolerability were detected with decreasing CL~CR~. Riociguat C~max~ and AUC ranges in patients with renal impairment overlapped those previously observed in healthy volunteers and patients with PH \[[@B2],[@B3]\].

###### 

Pharmacokinetic parameters of riociguat in healthy participants and in individuals with mild, moderate or severe renal impairment

  Parameter           Group 1 (CR~CL~ \> 80 mL/min) n = 16   Group 2 (CR~CL~ 50--80 mL/min) n = 15   Group 3 (CR~CL~ 30--49 mL/min) n = 16   Group 4^a^ (CR~CL~ \< 30 mL/min) n = 16
  ------------------- -------------------------------------- --------------------------------------- --------------------------------------- -----------------------------------------
  AUC, μg·h/L         245.7 (51)                             347.5 (111)                             499.0 (110)                             523.0 (70.4)^b^
  C~max,~ μg/L        36.6 (17)                              44.2 (21)                               42.0 (32)                               40.56 (37.8)^b^
  AUC~norm~, kg·h/L   20.6 (56)                              29.4 (126)                              42.1 (109)                              29.7 (102)
  C~max,norm~, kg/L   3.07 (17)                              3.48 (25)                               3.54 (30)                               2.97 (40)
  t~½~, h             6.19 (50)                              10.1 (116)                              11.4 (103)                              9.52 (75)

^a^In the first study, individuals with severe renal impairment (group 4) received riociguat 0.5 mg; all other participants in both studies received riociguat 1 mg.

^b^AUC and C~max~ values shown for individuals with severe renal impairment (group 4) are taken from the second study (n = 8), in which individuals with severe renal impairment received riociguat 1.0 mg.

Values are geometric means (percentage coefficient of variation). AUC, area under the plasma concentration--time curve from time 0 to infinity; AUC~norm~, AUC divided by dose per kilogram of body weight for total riociguat; C~max~, maximum concentration in plasma; C~max,norm~, C~max~ divided by dose per kilogram of body weight for total riociguat; t~½~, terminal elimination half-life for total riociguat.

![Box-and-whisker plot of riociguat AUC~norm~ (kg·h/L) after a single oral dose of riociguat. In the first study, individuals with severe renal impairment (group 4) received riociguat 0.5 mg; all other participants in both studies received riociguat 1 mg . Box, 25--75th percentile; vertical line, 10th--90th percentile; horizontal line, median; more extreme values are plotted as points; individuals eligible for pharmacokinetic analysis, n = 63; AUC~norm~, area under the plasma concentration--time curve from time 0 to infinity divided by dose per kilogram of body weight for total riociguat.](2050-6511-14-S1-P22-1){#F1}

Conclusion
==========

Exposure to riociguat was higher in individuals with renal impairment (CL~CR~ 15--80 mL/min) than in controls; particular care should be exercised during individual dose titration in patients with renal impairment.
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